A systematic review investigating the relationship between efficacy and stimulation parameters when using transcutaneous electrical nerve stimulation after knee arthroplasty

David Beckwée¹, Ivan Bautmans², Eva Swinnen¹, Yorick Vermet¹, Nina Lefeber¹, Pierre Lievens¹ and Peter Vaes¹

Abstract

Objective: To evaluate the clinical efficacy of transcutaneous electric nerve stimulation in the treatment of postoperative knee arthroplasty pain and to relate these results to the stimulation parameters used.

Data Sources: PubMed, Pedro and Web of Knowledge were systematically screened for studies investigating effects of transcutaneous electric nerve stimulation on postoperative knee arthroplasty pain.

Review Methods: Studies were screened for their methodological and therapeutic quality. We appraised the influence of the stimulation settings used and indicated whether or not a neurophysiological and/or mechanistic rationale was given for these stimulation settings.

Results: A total of 5 articles met the inclusion criteria. In total, 347 patients were investigated. The number of patients who received some form of transcutaneous electric nerve stimulation was 117, and 54 patients received sham transcutaneous electric nerve stimulation. Pain was the primary outcome in all studies. The stimulation settings used in the studies (n = 2) that reported significant effects differed from the others as they implemented a submaximal stimulation intensity. Stimulation parameters were heterogeneous, and only one study provided a rationale for them.

Conclusion: This review reveals that an effect of transcutaneous electric nerve stimulation might have been missed due to low methodological and therapeutic quality. Justifying the choice of transcutaneous electric nerve stimulation parameters may improve therapeutic quality.

Keywords
Transcutaneous electric nerve stimulation, knee arthroplasty, pain

Date received: 26 February 2014; accepted: 19 May 2014

Introduction

Rationale

Studies on the effectiveness of transcutaneous electric nerve stimulation (TENS) to relieve pain after knee arthroplasty differ in whether or not they find it to be efficacious. One reason might be that they have used different stimulation parameters, and some may be ineffective. A review, focusing on methodological quality of randomized controlled trials of TENS, identified different sources of bias that may lead to an underestimation of the treatment effect.¹ This review revealed that the main areas of concern were the location of application, the intensity and the duration of TENS. However, none of the included studies investigated TENS in patients with knee arthroplasty.

The number of osteoarthritis patients undergoing knee arthroplasty has increased dramatically in the last decades.² This trend will probably persist in the coming years given the worldwide demographic changes, the growing incidence of osteoarthritis, and the increased life expectancy.

¹Rehabilitation Sciences Research Department, Vrije Universiteit Brussel, Brussels, Belgium
²Gerontology and Frailty in Ageing Research Departments, Vrije Universiteit Brussel, Brussels, Belgium

Corresponding author:
Peter Vaes, Rehabilitation Sciences Research Department, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium.
Email: pvaes@vub.ac.be
overweight and obesity and the wish of elderly persons to maintain an active lifestyle. Knee arthroplasty is a procedure often accompanied with high levels of postoperative pain, which may hinder functional rehabilitation. Therefore, an effective pain management is of major importance to achieve good rehabilitation outcomes.

TENS is a non-pharmacological, inexpensive and safe form of postoperative analgesia treatment for which beneficial effects have been described after different surgical procedures. Its analgesic effects are attributed to mechanisms related to the “gate control” theory of pain and, as proven more recently, pathways involving the central nervous system.

Objectives
The aim of this systematic literature review is to evaluate the clinical efficacy of TENS in the treatment of postoperative pain in knee arthroplasty patients and to relate this to the stimulation parameters used. All studies were screened for their methodological quality. In addition to this, we assessed the fidelity criteria for application of TENS for pain in clinical trials (i.e. potential sources of bias that may lead to underestimation of treatment effects), as proposed by Bennett et al.

Materials and methods
Eligibility criteria
Trials studying the effect of TENS on pain, range of motion (ROM) or function following knee arthroplasty were considered.

Information sources
PubMed, Pedro and Web of Knowledge were systematically screened. Additional studies were identified by scanning the reference lists of included articles (last search in November 2013).

Search
We used the following search terms to search both databases: post-surgery knee arthroplasty, after operation knee arthroplasty, knee replacement, knee arthroplasty, knee prosthesis, TENS, transcutaneous electrical nerve stimulation, percutaneous electrical nerve stimulation, pain, function and ROM (see Appendix 1 for full search strategy). The following language limits were applied: English, French or Dutch. No publication date or status restrictions were imposed.

Study selection
Eligibility assessment was performed independently by two investigators (D.B. and Y.V.). Disagreements between reviewers were resolved by consensus.

Data items
Information was extracted from each included study on the following: study set-up (including description of study arms, medication being used as co-intervention), type of intervention (including requirements for application of TENS for pain in clinical trials, as proposed by Bennett et al., active area of the electrode, wave form, number of electrodes, location of the electrodes, pulse duration, stimulation frequency, intensity, duration of one treatment session, period of treatment) and type of outcome measures. As a supplementary criterion, we screened for a neurophysiological and/or mechanistic rationale for the stimulation parameters that were used.

Risk of bias in individual studies
The methodological quality of the included studies was assessed by two independent investigators (D.B. and I.B.), using the methodology checklist for randomized controlled trials of the National Institute for Health and Clinical Excellence (NICE) (http://www.nice.org.uk/guidelinesmanual; last checked 22 February 2013). This checklist focuses on potential risks of selection, performance, attrition and detection bias.

Results
Study selection
Five studies met the inclusion criteria (Figure 1).

Study characteristics
The study characteristics are shown in Table 1. All studies were prospective randomized trials. Two of the included articles were from the same research group and report probably on the same cohort. They both have used the same or comparable outcome variables and interventions. Walker et al. described a supplementary intervention arm treated by a continuous cooling pad (CCP). For the scope of this review, only the TENS-related results were extracted.

Participants
In total, 347 patients were investigated (Figure 2; Table 1). The total number of patients who received some form of TENS was 117, and 54 patients received sham TENS. One study included participants following either total hip replacement or knee arthroplasty (n = 107, of which 43 received TENS and 22 received sham TENS) but did not provide specific data for knee arthroplasty patients solely (Table 1).

Intervention
Two articles described the effect of TENS in three comparable treatment groups: continuous passive motion (n = 12),
continuous passive motion in combination with “subthreshold” TENS (n = 18) and continuous passive motion in combination with “sensory threshold” TENS (n = 18).\(^\text{11,12}\) Both articles reported effects on active knee flexion, the use of analgesics, the length of hospital stay,\(^\text{12}\) and visual analog scale (VAS) for pain.\(^\text{11}\) Breit and Van der Wall\(^\text{13}\) studied the effect of TENS in combination with patient-controlled analgesia. Their study contained three study arms: patient-controlled analgesia (n = 22), patient-controlled analgesia combined with TENS (n = 25) and patient-controlled analgesia combined with sham TENS (n = 22). Stabile and Mallory\(^\text{10}\) studied the effects of TENS (n = 43) compared to sham TENS (n = 22) or treatment with intramuscular Dilaudid (hydromorphone HCl) (n = 42). Wanich et al.\(^\text{14}\) studied a patented device called “Deepwave” which sends a modulation of two high-frequency (HF) currents between two electrodes that comprised microneedles. This study involves an experimental group (n = 13) and a sham group (n = 10).

Outcomes

Pain was used as the primary outcome variable in all included studies and was quantified by VAS\(^\text{11,13,14}\) and/or analgesic consumption.\(^\text{10–14}\) In one study, VAS data could not be interpreted because of missing data and inconsistencies.\(^\text{13}\) Analgesic consumption was quantified by standardized medication intake using a parenteral and oral dosage equivalence system\(^\text{12}\) or a bioequivalent scale (BEQ).\(^\text{11}\) These equivalence systems were devised for the narcotic medications used by the patient sample and based on a comparative dosage of injectable narcotic medication. Other quantification methods used for analgesic consumption were dose of spinal anesthesia,\(^\text{13}\) dose of sedation\(^\text{13}\) and amount of postoperative morphine.\(^\text{10,13}\)

Risk of bias within studies

Overall, methodological quality of the included studies was poor and risk of bias was present with a likely overestimation of the treatment effect (Table 2). All studies involved a relatively low sample size (N = 25 or lower per intervention arm), and none of the studies reported a priori sample size calculation or power analysis. There was a lack of information regarding the number of subjects that were excluded or dropped out. One study mentioned the withdrawal of two subjects from the experimental group because they were unwilling (due to fatigue) to comply with twice daily treatments.\(^\text{14}\) Only one study registered adverse effects.\(^\text{10}\) Although participants of all included studies were randomly
| Study                  | Subjects          | Study arms                                                                 | Medication as co-intervention for (sham) TENS | Outcome                                                                 | Results                                                                                                                                 |
|-----------------------|-------------------|----------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Angulo and Colwell    | TKA (n = 48)      | (G1) CPM (n = 12)                                                         | Morphine (demerol)                            | (1) % decrease VAS                                                       | VAS (mean % decrease in postoperative day 1–3): G2 = 0.499 ± 0.456 G3 = 0.379 ± 0.542 (p > 0.05) BEQ (day 1–day 3): No between-group differences (p > 0.05) |
|                       |                   | (G2) CPM + sensory threshold TENS (40 mA) (n = 18)                        | Dilaudid                                      | (2) BEQ                                                                  |                                                                                                                                         |
|                       |                   | (G3) CPM + subthreshold TENS (14 mA) (n = 18)                             | Hydrocodone (vicodin)                         | (3) ROM active knee flexion                                              |                                                                                                                                         |
|                       |                   |                                                                          | Oxycodone (percodan–percocet po)              | (4) Length of hospital stay (LoS)                                        | No data provided no between-group differences (p > 0.05) LoS: G1 = 7.1 days ± 0.79 G2 = 7.6 days ± 0.89 G3 = 7.6 days ± 0.89 no between-group differences (p > 0.05) |
| Breit and Van der Wall| TKA (n = 69)      | - PCA (n = 22)                                                            | Morphine                                     | (1) VAS for pain                                                        | - VAS not interpreted due to data loss - No between-group differences for sedation dosage, spinal anesthesia and PCA (p > 0.01) - No information on within-group differences |
|                       |                   | - PCA + TENS (n = 25)                                                    |                                               | (2) Spinal anesthesia dosage                                             |                                                                                                                                         |
|                       |                   | - PCA + sham TENS (n = 22)                                                |                                               | (3) Sedation dosage                                                     |                                                                                                                                         |
| Walker et al.         | TKA (n = 100)     | Phase I                     | Intramuscular:                               | (4) Morphine PCA (first 24 h)                                           | - EAD during TENS: G1 = 61EAD (22–113) G2 = 59EAD (14–127) G3 = 66EAD (9–170) No between-group differences (p > 0.05) EAD total: G1 = 87EAD (27–187) G2 = 87EAD (24–188) G3 = 93EAD (17–220) No between-group differences (p > 0.05) |
|                       | (n = 22)          | - CPM (n = 12)                                                           | Meperidine (Demerol)                         | (1) EAD during TENS                                                      |                                                                                                                                         |
|                       |                   | - No CPM (n = 10)                                                        | Prophine sulfate                             | (2) EAD total                                                           |                                                                                                                                         |
|                       | Phase 2           | (n = 48)                                                                 | Hydromorphone (Dilaudid)                     | (3) length of hospital stay (LoS)                                        |                                                                                                                                         |
|                       |                   | - (G1) CPM (n = 12)                                                     | Oral:                                        | (4) ROM flexion day 3                                                   |                                                                                                                                         |
|                       |                   | - (G2) CPM + sensory threshold TENS (40 mA) (n = 18)                     | Oxycodone (percodan–percocet)                | (5) ROM flexion discharge                                              |                                                                                                                                         |
|                       | Phase 3           | (n = 30)                                                                 | Hydrocodone (vicodin)                        |                                                                         |                                                                                                                                 |
|                       |                   | - CPM (n = 15)                                                           | Codeine (tylenol no. 3)                      |                                                                         |                                                                                                                                 |
|                       |                   | - CPM + CCP (n = 15)                                                    | Propoxyphene (darvocet N100)                 |                                                                         |                                                                                                                                 |
| Study                        | Subjects | Study arms                        | Medication as co-intervention for (sham) TENS | Outcome                                      | Results                                                                                                                                                                                                 |
|------------------------------|----------|-----------------------------------|------------------------------------------------|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Beckwee et al.               |          |                                   |                                                |                                              | LoS: G1 = 7.1 days (6–9) G2 = 7.8 days (7–10) G3 = 7.4 days (6–9) No between-group differences (p > 0.05) ROM day 3: G1 = 76° (65–85) G2 = 74° (60–100) G3 = 78° (64–94) ROM discharge: G1 = 84° (65–95) G2 = 84° (75–105) G3 = 89° (64–94) - No information on within-group differences provided |
| Stabile and Mallory¹⁰       | TKA and THA (n = 107) | - (G1) intramuscular narcotic Dilaudid (n = 42) | - Dilaudid on demand                           | Amount of narcotic on days 1, 2, 3 (Dilaudid; mg/day) | G2 and G3: Significantly less narcotic in G2 and G3 (p < 0.05); no data provided G2 and G3: 86% indicate that “TENS helped in the management of discomfort and lessened the need for the narcotic medication” |
| Wanich et al.¹⁴             | TKA (n = 23) | - (G1) Deepwave (n = 13)           | ns                                             | Brief Pain Inventory (BPI), including VAS for pain - Type and dose of medication | VAS: G1 before treatment = 28 G1 after treatment = 19 significant within-difference (p < 0.05) G2 before treatment = 26 G2 after treatment = 25 No significant within-difference (p > 0.05) G1 versus G2: Significant between-difference (p < 0.05) Opioid use: Trend to decreased opioid use in G1 (p = 0.09); no data provided |
assigned to comparison groups, only two studies provided some information on the randomization procedure.13,14 All studies involved a control group which did not receive any form of TENS. Two included articles mentioned blinding of therapists11,12 However, in the study by Angulo and Colwell,11 therapists were only blinded to the intensity of TENS being applied (40 mA in group 1 vs 14 mA in group 2) by hiding the intensity indicator with adhesive tape, but they did not mention whether they were blinded for treatment allocation. Walker et al.12 mentioned that therapists were blinded for group allocation and outcome measurements. In all studies, the investigators attempted to blind the participants for the study interventions.10–14 Patients were blinded by either hiding the intensity indicator with adhesive tape,11 by leaving the intensity at zero,14 by placing unconnected wires under the blankets so that the machine appears connected to the electrodes13 or by using TENS units without power supply (no batteries).10 Walker et al.12 mentioned blinding of patients “as to parameters under study” without further specification. In two studies, participants who had knowledge of or had previously used a TENS machine were excluded for participation.11,13

Application fidelity

None of the included studies match all the requirements for TENS application as stated by Bennett et al.1 (Table 2). One study12 (80%) did not report if TENS was used over the area of pain or segmental area and only 210,14 (40%) used TENS at an adequate intensity. Three studies11,13,14 (60%) mention that TENS is applied for at least 30 min.

Rationale

No study provided a neurophysiological or mechanistic rationale for the stimulation parameters used.10–14 Although Wanich et al. claimed to use a special waveform which is based on a new technology that is supported by the theory of hyperpolarization for inhibiting pain transmission, the authors did not provide reference to scientific evidence for this. They combined two HF electronic waveforms with the aim of interrupting sodium/potassium ion exchange across the membrane of the C-fiber, inhibiting cell wall from changing polarity and impeding transmissions of pain impulses.14 Wanich et al. presented some information concerning the electrodes that comprised microneedles to facilitate the delivery of the current through the skin but also did not provide any reference to scientific proof for this assumption.

Results of individual studies

Two studies found a beneficial effect of TENS on pain.10,14 Both studies implemented a submaximal stimulation intensity, perceived as “strong but comfortable” (Table 3). None of the other studies used this intensity setting. While Wanich et al. set this parameter after the surgery, Stabile and Mallory10 preoperatively obtained values for pulse width and frequency that gave the patient this strong sensation. Wanich et al. applied the TENS twice daily for 30 min, but Stabile and Mallory did not report on the duration or the frequency of a treatment session. In both studies, HF TENS was used. Wanich et al. started the intervention at 36/48 h post-surgery after the removal of the Dilaudid/bupivacaine epidural, but they did not report on opioid intake or other pain control as an adjunct for the electrical stimulation. However, they report a trend towards a decreased opioid use in the experimental group, but it is not clear how and when this opioid use was provided and registered. They also found a significant decrease in VAS pain scores (p < 0.05) in the experimental group (decrease in VAS from 28/100 to 19/100) compared to the control group (decrease in VAS from 26/100 to 25/100). In contrast, the patients in the study of Stabile and Mallory10 started the TENS “as soon as the patient awoke from surgery and complained from pain,” and they were offered Dilaudid as an adjunct for pain control. In the latter study, the postoperative pain control, determined by the amount of milligrams per day of Dilaudid on the first, second and third postoperative days, was significantly lower in the experimental and placebo group than in the control group. This finding was supported by the subjective opinion
Table 2. Methodological checklist: randomized controlled trials (©National Institute for Health and Clinical Excellence, March 2012)(y: yes; n: no, u: unclear; n/a: not applicable).

|                  | Stabile and Mallory\(^{10}\) | Angulo and Colwell\(^{11}\) | Walker et al.\(^{12}\) | Breit and Vander Wall\(^{13}\) | Wanich et al.\(^{14}\) |
|------------------|-------------------------------|-------------------------------|--------------------------|--------------------------------|--------------------------|
| A. Selection bias |                               |                               |                          |                                |                          |
| A1. Randomization method (yes, no, unclear, n/a) | y                             | y                             | y                        | y                             | y                        |
| A2. Concealment of allocation (yes, no, unclear, n/a) | u                             | u                             | u                        | y                             | y                        |
| A3. Group comparability at baseline (yes, no, unclear, n/a) | u                             | y                             | y                        | u                             | y                        |
| Risk of bias (low, unclear/unknown, high) | u                             | Low                           | u                        | Low                           | u                        |
| Likely direction of effect | Overestimation | Overestimation | Overestimation | Unclear | Unclear |
| B. Performance bias |                               |                               |                          |                                |                          |
| B1. Comparison group: same care apart from intervention studied (yes, no, unclear, n/a) | u                             | y                             | y                        | y                             | u                        |
| B2. Blinding of participants (yes, no, unclear, n/a) | y                             | y                             | y                        | y                             | y                        |
| B3. Blinding care providers (yes, no, unclear, n/a) | u                             | y                             | y                        | u                             | n                        |
| Risk of Bias (low, unclear/unknown, high) | u                             | Low                           | Low                     | Low                           | High                     |
| Likely direction of effect | Overestimation | n/a                         | n/a                     | Overestimation | Overestimation |
| C. Attrition bias |                               |                               |                          |                                |                          |
| C1. Follow-up: equal length of time (yes, no, unclear, n/a) | y                             | y                             | y                        | y                             | u                        |
| C2. a. Drop outs (N) | u                             | 0                             | 0                        | u                             | 2                        |
| C2. b. Treatment completion: groups comparable? (yes, no, unclear, n/a) | u                             | n/a                           | n/a                      | u                             | n                        |
| C3. a. Data loss (N) | u                             | u                             | u                        | u                             | u                        |
| C3. b. Data loss: groups comparability? (yes, no, unclear, n/a) | u                             | u                             | u                        | u                             | u                        |
| Risk of bias (low, unclear/unknown, high) | u                             | u                             | u                        | u                             | u                        |
| Likely direction of effect | Overestimation | Overestimation | Overestimation | Unclear | Unclear |
| D. Detection bias |                               |                               |                          |                                |                          |
| D1. Follow-up: appropriate length? (yes, no, unclear, n/a) | y                             | y                             | y                        | n                             | u                        |
| D2. Outcome: precise definition? (yes, no, unclear, n/a) | y                             | y                             | y                        | y                             | u                        |
| D3. Outcome determination: valid and reliable? (yes, no, unclear, n/a) | y                             | y                             | y                        | y                             | y                        |
| D4. Blinding investigator to participant’s exposure to the intervention? (yes, no, unclear, n/a) | u                             | u                             | u                        | u                             | n                        |
| D5. Blinding investigator to other confounding/prognostic factors? (yes, no, unclear, n/a) | u                             | u                             | u                        | u                             | u                        |
| Risk of bias (low, unclear/unknown, high) | Low                           | Low                           | Low                     | High                           | High                     |
| Likely direction of effect | Overestimation | Overestimation | Overestimation | Unclear | Unclear |
| E. Rationale |                               |                               |                          |                                |                          |
| E1. Was a neurophysiological and/or mechanistic rationale given for the stimulation parameters used? (yes, no, unclear, n/a) | n                             | n                             | n                        | n                             | n                        |
of the patients from the experimental and placebo groups: 86% of them felt that “TENS helped in the management of their discomfort and lessened the need for the narcotic medication.” However, the placebo effect was not significant.

In contrast, three studies did not show that TENS or sham TENS significantly altered analgesia consumption.11–13 They all applied TENS continuously 24 h/day. Two of these studies reports were, as previously mentioned, from the same research group. They used a stimulation frequency of 70 Hz and fixed-pulse amplitudes of 14 mA (below sensory threshold) and 40 mA (above sensory threshold).11,12 These intensities were based on a preoperative test of 13 subjects in which the “mean level of the sensory threshold” (i.e. 21 mA) and the “mean maximum comfortable sensory stimulation below the level of visible muscle contraction” (i.e. 40 mA) were determined. No significant differences in percentage decrease of VAS scores for pain were demonstrated between the “subthreshold” and the “sensory threshold” TENS treatments.11 No clear rationale was given for this procedure to obtain the stimulation parameters, and no information was given concerning the VAS scores of the control group.

**TENS parameters**

A wide range of TENS parameters were used in the included studies (Table 3). Three studies reported the number of electrodes used: two11,14 or four.13 Four studies reported on the location of the electrodes: one10,11,14 or two electrodes (above and beneath the knee)13 on the medial and lateral aspects of the operated knee. One study did not provide any information on the number, type or placement of electrodes.12 The electrodes used by Wanich et al.14 were made to facilitate the delivery of the feed signals through the skin by 1014 microneedles that are 0.74 mm in length within a 2.5-in-diameter sterile patch. One study applied stimulation intensities that were controlled by the patient,13 but they were not registered or reported. One study did not provide information on pulse width and frequencies.13 TENS was used continuously during the first postoperative 24 h13 or the first three postoperative days.11,12 One study did not specify the duration of the TENS treatment.10 Wanich et al.14 used a premixed modulated envelope of two HF electronic waveforms.

**Discussion**

In this review, we aimed to evaluate the clinical efficacy of TENS in the postoperative treatment of knee arthroplasty. We included five study reports of which two showed a positive effect of TENS on analgesia consumption10 or subjective measures of pain.14 These were the only studies that used a stimulation intensity that was perceived as “strong but comfortable,” which is in accordance with latest guidelines.1 However, all included articles showed poor methodological quality with a risk of overestimation of the effects. An important finding of our review is the lack of articles providing clear, transparent and sufficiently detailed information which is in line with the conclusions of a previous review.1 In the future, TENS studies should follow the international standards for reporting randomized controlled trials, such as provided by the Consolidated Standards of Reporting Trials Group (CONSORT).15

When assessing the quality of the included studies, we took additional criteria into account that were previously presented by Bennett et al.1 and that are related to application fidelity. Our findings are in line with Bennett’s results: the quality of the TENS interventions that are used in the included studies show multiple areas of concern that may

| Study                      | Electrode: active area | Wave form                      | No. of electrodes | Electrode location | Pulse duration | Stimulation frequency | Intensity | Duration of session | Period |
|----------------------------|------------------------|--------------------------------|--------------------|-------------------|-----------------|----------------------|-----------|---------------------|--------|
| Angulo and Colwell11       | 13.5 cm × 2.5 cm       | Symmetrical biphasic            | 2                  | 3–5 cm, parallel to incision | 100 µs          | 70 Hz                | G1 = 40 mA, G2 = 14 mA | 24 h/day | 3 days              |
| Walker et al.12            | ns                     | ns                             | ns                 | Both sides of incision | 120–200 µs      | 10–100 Hz            | lla = 40 mA, lla = 14 mA | 24 h/day | 3 days              |
| Stable and Mallory12       | ns                     | ns                             | ns                 | On the medial and lateral aspects of the operated knee | ns               | High frequency        | Strong but comfortable tingling/pressure sensation | As soon as patient awoke from surgery and complained from pain; duration not mentioned | After epidural removal until discharge |

TENS: transcutaneous electric nerve stimulation; d: pulse width; f: pulse frequency; ns: specified.
underestimate the effects of TENS. The criteria proposed by Bennett et al.\textsuperscript{1} may be used for judging sources of potential bias related to TENS application, but their checklist does not take into account the rationale that researchers have been using to justify their choice of stimulation parameters. Hoogeboom et al.\textsuperscript{16} state that the rationale for choosing an intervention (including its parameters) and whether this is based on good scientific evidence may add to the quality of an intervention. A study can be perfectly set up methodologically, but if the quality of the intervention is weak, study results are susceptible to bias. Especially for non-pharmacological therapies, justifying the choice of the therapy (including its components such as intensity, frequency) is an important feature of evidence-based practice. Therefore, when interpreting the results of the included studies of our review, we did not only consider the stimulation parameters but also the rationale for using them. We think that this is an important asset of our review. Only one study in this review provided rationales for the stimulation settings being used, but none of them were scientifically empowered.\textsuperscript{14}

Knowing the rationale for the procedure of preoperatively assessing TENS settings that will be used for TENS treatment after surgery would give more insight in the decision-making and reasoning process of the researchers.\textsuperscript{10–12} In this context, it should be noted that sensation alterations exist in the skin following knee arthroplasty,\textsuperscript{17} and thus, preoperatively assessed parameters corresponding to “strong but non-painful”\textsuperscript{10} or “maximum comfortable”\textsuperscript{11} stimulation may not always reflect the postoperative sensations.

Previously, placebo TENS has shown similar effects to active TENS,\textsuperscript{18} and therefore, it is essential to incorporate a well-constructed sham TENS device that not only blinds the patient but also the investigator.\textsuperscript{19} Especially, the treatment allocation should be concealed for the outcome assessors in order to avoid bias.\textsuperscript{1} All of the included studies of our review tried to blind the patients in a way that therapist could be aware of the treatment allocation, that is, they were not blinded for the treatment (e.g. pulling out batteries or using unconnected wires).\textsuperscript{10,13} Therefore, a separate blinded investigator is needed to assess the outcomes. Recently, a new sham TENS device has been proposed that allows blinding the investigator while delivering a placebo treatment.\textsuperscript{19} This device delivers stimulation for 30 s and gradually decreases to 0 over the next 15 s.

All of the included studies took medication intake as an outcome measure. An important feature to take into account when interpreting TENS results is the use of analgesics and more specifically opioids because TENS-induced analgesia also involves opioid receptors.\textsuperscript{20,21} Therefore, a possible interaction between TENS and opioid use may exist. Moreover, low-frequency (LF) TENS seemed ineffective in rats that were made previously tolerant to opioids.\textsuperscript{22} So, LF TENS might be ineffective in patients using opioids due to analgesic tolerance. In all of the included studies, TENS has been used following or during the use of opioids. However, all studies except one\textsuperscript{13} reported the use of HF TENS. In contrast, instead of hindering each other’s effect, a combination of TENS with pharmacological agents has previously been proven to enhance the effectiveness of the treatment.\textsuperscript{23,24} For example, clonidine is a pharmacological agent that produces an alpha-2 adrenergic-mediated anti-nociceptive effect, because of which its potency is increased when it is combined with TENS.\textsuperscript{24} Consequently, a lower dose of the drug could produce a similar degree of analgesia, thus diminishing the risk of drug-related side effects.

The three studies that did not find an anti-nociceptive effect of TENS applied TENS continuously 24 h/day.\textsuperscript{11–13} In this respect, it is interesting to note that previously it has been proven that both HF and LF TENS may produce analgesic tolerance.\textsuperscript{25–28} However, this occurs through different pathways.\textsuperscript{29–31} Since burst TENS is a combination of LF TENS and HF TENS, it may generate a combination of analgesic action of both LF TENS and HF TENS and by doing so delaying or limiting analgesic tolerance. Thus, in the future, it would be interesting to investigate the analgesic effects of burst TENS following knee arthroplasty.

Two of the three studies that did not find a significant effect of TENS used continuous passive motion during the hospitalization period for 20 h/day.\textsuperscript{11,12} Besides the fact that continuous passive motion has not been shown to provide added value to the rehabilitation outcomes,\textsuperscript{32} the long period of continuous passive motion that is applied in the studies may initiate central sensitization.\textsuperscript{33} By continuously activating polymodal nociceptors and stimulating the release of pro-inflammatory cytokines, the continuous passive motion may initiate central sensitization resulting in an altered responsiveness to electrical stimuli. This may lead to an underestimation of the TENS effects.

Our study has several limitations. We a priori set the eligibility criteria, including the language restrictions for including studies. We think that by adding French and Dutch alongside English, we increased the chance of getting a comprehensive search result. However, we are aware that language restriction may increase the risk on influencing the effect estimates. Nevertheless, a study of Jüni et al.\textsuperscript{34} showed that excluding trials published in languages other than English has generally little effect on summary treatment effect estimates. As mentioned previously, the overall quality of the included studies (methodologically and therapeutically) was poor, and this may lead to substantial over- or underestimations of the reported effects. Publication bias may account for some of the presented effects. Two studies were from the same research group. They both reported the same or comparable study groups, outcome measures and used the same TENS settings. Therefore, it cannot be ruled out that these studies should be treated as one. Due to the low number of studies that report effects of TENS in this specific population and due to the incomplete reporting of the study designs, interpretation and applicability of our review may be restricted. However, based on the findings of our review,
we propose some advices to take into account when using TENS in a clinical setting: (1) the intensity of the current should be perceived as strong but comfortable, (2) HF TENS should be used, (3) therapists should be aware of the rationale for each TENS parameter and (4) burst TENS may combine analgesic effects of HF TENS and LF TENS. We also propose some recommendations when designing TENS studies in hospitalized knee arthroplasty patients: (1) CONSORT recommendations should be incorporated when designing and reporting trials; (2) when applying TENS, the fidelity criteria as proposed by Bennett et al. should be taken into account; (3) the use of a sham TENS device as proposed by Rakel et al. allows blinding of the investigator while delivering the placebo treatment, and thus, a separate blinded investigator is not needed to assess the outcomes; (4) the use of burst TENS should be considered since this may produce a combination of the mechanisms of action of both LF and HF TENS and (5) interactions between TENS and medication is a promising study field that may help to provide a more effective pain management with less drug-related side effects.

We conclude that the majority of the included studies point out that TENS has no analgesic effect in knee arthroplasty patients. However, the two studies that used TENS intensities as advised by the recent scientific literature did report significant analgesic effects. All studies showed poor methodological quality and are heterogeneous in study design and outcome. Supplementary well-designed studies are needed to determine whether TENS can counter postoperative knee arthroplasty pain.

**Declaration of conflicting interests**

The authors declare that they have no competing interests.

**Funding**

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**References**

1. Bennett MI, Hughes N and Johnson MI. Methodological quality in randomised controlled trials of transcutaneous electric nerve stimulation for pain: low fidelity may explain negative findings. *Pain* 2011; 152: 1226–1232.

2. Otten R, van Roermund PM and Picavet HS. Trends in the number of knee and hip arthroplasties: considerably more knee and hip prostheses due to osteoarthritis in 2030. *Ned Tijdschr Geneeskd* 2010; 154: A1534.

3. Capdevila X, Barthelet Y, Biboulet P, et al. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. *Anesthesiology* 1999; 91: 8–15.

4. Chesterton LS, van der Windt DA, Sim J, et al. Transcutaneous electrical nerve stimulation for the management of tennis elbow: a pragmatic randomized controlled trial: the TATE trial (ISRCTN 87141084). *BMC Musculoskelet Disord* 2009; 10: 156.

5. Cipriano G Jr, de Camargo Carvalho AC, Bernardelli GF, et al. Short-term transcutaneous electrical nerve stimulation after cardiac surgery: effect on pain, pulmonary function and electrical muscle activity. *Interact Cardiovasc Thorac Surg* 2008; 7: 539–543.

6. Erdogan M, Erdogan A, Erbil N, et al. Prospective, randomized, placebo-controlled study of the effect of TENS on postthoracotomy pain and pulmonary function. *World J Surg* 2005; 29: 1563–1570.

7. DeSantana JM, Santana-Filho VJ, Guerra DR, et al. Hypoalgesic effect of the transcutaneous electrical nerve stimulation following inguinal herniorrhaphy: a randomized, controlled trial. *J Pain* 2008; 9: 623–629.

8. Melzack R and Wall PD. Pain mechanisms: a new theory. *Science* 1965; 150(699): 971–979.

9. DeSantana JM, Walsh DM, Vance C, et al. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. *Curr Rheumatol Rep* 2008; 10: 492–499.

10. Stabile ML and Mallory M. The management of postoperative pain in total joint replacement: transcutaneous electrical nerve stimulation is evaluated in total hip and knee patients. *Orthop Rev* 1978; 7: 121–123.

11. Angulo DL and Colwell CW. Use of postoperative TENS and continuous passive motion following total knee replacement. *J Orthops Phys Ther* 1990; 11: 599–604.

12. Walker RH, Morris BA, Angulo DL, et al. Postoperative use of continuous passive motion, transcutaneous electrical nerve stimulation, and continuous cooling pad following total knee arthroplasty. *J Arthroplasty* 1991; 6: 151–156.

13. Breit R and Van der Wall H. Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty. *J Arthroplasty* 2004; 19: 45–48.

14. Wanich T, Gelber J, Rodeo S, et al. Percutaneous neuromodulation pain therapy following knee replacement. *J Knee Surg* 2011; 24: 197–202.

15. Schulz KF, Altman DG and Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2011; 9: 672–677.

16. Hoogeboom TJ, Oosting E, Vriezekolk JE, et al. Therapeutic validity and effectiveness of preoperative exercise on functional recovery after joint replacement: a systematic review and meta-analysis. *PLoS One* 2012; 7: e38031.

17. Hassaballa M, Artz N, Weale A, et al. Alteration in skin sensation following knee arthroplasty and its impact on kneeling ability: a comparison of three common surgical incisions. *Knee Surg Sports Traumatol Arthrosoc* 2012; 20: 1983–1987.

18. Oosterhof J, Samwel HJ, de Boo TM, Wilder-Smith OH, Oostendorp RA and Crul BJ. Predicting outcome of TENS in chronic pain: a prospective, randomized, placebo controlled trial. *Pain* 2008; 136: 11–20.

19. Rakel B, Cooper N, Adams HJ, et al. A new transient sham TENS device allows for investigator blinding while delivering a true placebo treatment. *J Pain* 2010; 11: 230–238.

20. Resende MA, Sabino GG, Candido CR, et al. Local transcutaneous electrical stimulation (TENS) effects in experimental inflammatory edema and pain. *Eur J Pharmacol* 2004; 504: 217–222.
21. Sabino GS, Santos CM, Francischi JN, et al. Release of endogenous opioids following transcutaneous electric nerve stimulation in an experimental model of acute inflammatory pain. *J Pain* 2008; 9: 157–163.

22. Sluka KA, Judge MA, McColley MM, et al. Low frequency TENS is less effective than high frequency TENS at reducing inflammation-induced hyperalgesia in morphine-tolerant rats. *Eur J Pain* 2000; 4: 185–193.

23. Sluka KA. Systemic morphine in combination with TENS produces an increased antihyperalgesia in rats with acute inflammation. *J Pain* 2000; 1: 204–211.

24. Sluka KA and Chandran P. Enhanced reduction in hyperalgesia by combined administration of clonidine and TENS. *Pain* 2002; 100: 183–190.

25. Hingne PM and Sluka KA. Blockade of NMDA receptors prevents analgesic tolerance to repeated transcutaneous electrical nerve stimulation (TENS) in rats. *J Pain* 2008; 9: 217–225.

26. DeSantana JM, da Silva LF and Sluka KA. Cholecystokinin receptors mediate tolerance to the analgesic effect of TENS in arthritic rats. *Pain* 2010; 148: 84–93.

27. Liebano RE, Rakel B, Vance CG, et al. An investigation of the development of analgesic tolerance to TENS in humans. *Pain* 2011; 152: 335–342.

28. Chandran P and Sluka KA. Development of opioid tolerance with repeated transcutaneous electrical nerve stimulation administration. *Pain* 2003; 102: 195–201.

29. Sluka KA, Deacon M, Stibal A, et al. Spinal blockade of opioid receptors prevents the analgesia produced by TENS in arthritic rats. *J Pharmacol Exp Ther* 1999; 289: 840–846.

30. Sluka KA, Vance CG and Lisi TL. High-frequency, but not low-frequency, transcutaneous electrical nerve stimulation reduces aspartate and glutamate release in the spinal cord dorsal horn. *J Neurochem* 2005; 95: 1794–1801.

31. Sluka KA, Lisi TL and Westlund KN. Increased release of serotonin in the spinal cord during low, but not high, frequency transcutaneous electric nerve stimulation in rats with joint inflammation. *Arch Phys Med Rehabil* 2006; 87: 1137–1140.

32. Harvey LA, Brosseau L and Herbert RD. Continuous passive motion following total knee arthroplasty in people with arthritis. *Cochrane Database Syst Rev* 2010; 3: CD004260.

33. Nijs J, Van Houdenhove B and Oostendorp RAB. Recognition of central sensitization in patients with musculoskeletal pain: application of pain neurophysiology in manual therapy practice. *Man Ther* 2010; 15: 135–141.

34. Jüni P, Holenstein F, Sterne J, et al. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. *Int J Epidemiol* 2002; 31: 115–123.
### Appendix I

#### Search strategy

**Database:** PubMed

**User query:**

(post-surgery knee arthroplasty OR after operation knee arthroplasty OR knee replacement OR knee arthroplasty OR knee prosthesis) AND (TENS OR transcutaneous electrical nerve stimulation OR percutaneous electrical nerve stimulation) AND (pain OR function OR range of motion) AND (English [lang] OR Dutch [lang] OR French [lang]) NOT review

**Query translations**

| Query            | Translation                                                                 |
|------------------|-----------------------------------------------------------------------------|
| Knee arthroplasty| “arthroplasty, replacement, knee”[MeSH Terms] OR (“arthroplasty”[All Fields] AND “replacement”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee arthroplasty”[All Fields]) OR (“arthroplasty, replacement, knee”[MeSH Terms]) OR (“arthroplasty”[All Fields] AND “replacement”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) OR (“arthroplasty, replacement, knee”[MeSH Terms]) OR (“arthroplasty”[All Fields] AND “replacement”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) |
| Post-surgery     | “postoperative period”[MeSH Terms] OR (“postoperative”[All Fields] AND “period”[All Fields]) OR (“postoperative period”[All Fields] OR (“post”[All Fields] AND “surgery”[All Fields]) OR (“post surgery”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee arthroplasty”[All Fields]) OR (“arthroplasty, replacement, knee”[MeSH Terms]) OR (“arthroplasty”[All Fields] AND “replacement”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) |
| Operation        | “surgical procedures, operative”[MeSH Terms] OR (“surgical”[All Fields] AND “procedures”[All Fields] AND “operative”[All Fields]) OR (“operative surgical procedures”[All Fields]) OR (“surgery”[All Fields] AND “operative”[All Fields]) OR (“surgical procedures”[All Fields]) OR (“operative”[All Fields]) OR (“operation”[All Fields]) |
| Knee replacement | “arthroplasty, replacement, knee”[MeSH Terms] OR (“arthroplasty”[All Fields] AND “replacement”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee arthroplasty”[All Fields]) OR (“arthroplasty”[All Fields] AND “replacement”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) OR (“knee”[All Fields] AND “arthroplasty”[All Fields]) OR (“knee replacement arthroplasty”[All Fields]) |
| Knee prosthesis  | “knee prosthesis”[MeSH Terms] OR (“knee”[All Fields] AND “prosthesis”[All Fields]) OR (“knee replacement”[All Fields]) }
1. Angulo DL and Colwell CW. Use of postoperative TENS and continuous passive motion following total knee replacement. *J Orthop Sports Phys Ther* 1990; 11(12): 599–604 (PMID: 18787258).

2. Baldwin MA, Clary CW, Fitzpatrick CK, et al. Dynamic finite element knee simulation for evaluation of knee replacement mechanics. *J Biomech* 2012; 45(3): 474–83. Epub ahead of print 30 December 2011. DOI:10.1016/j.jbiomech.2011.11.052 (PMID: 22209313).

Different regimen

3. Breit R and Van der Wall H. Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty. *J Arthroplasty* 2004; 19(1): 45–48 (PMID: 14716650).

4. Cummings M. Referred knee pain treated with electroacupuncture to iliopsoas. *Acupunct Med* 2003; 21(1–2): 32–35 (PMID: 12924845).

Different regimen

5. Grouille D, Orsel I, Ledan C, et al. Postoperative analgesia after major surgery of the knee. *Ann Fr Anesth Reanim* 1998; 17(3): 281–282 (in French) (PMID: 9750744).

Different regimen

6. Kim SB, Kim JY, Park SW, et al. Comparison of 2 methods of non-invasive treatment between transcutaneous electrical stimulation and pulsed electromagnetic field stimulation as replacement of invasive manual acupuncture. *Acupunct Electrother Res* 2012; 37(4): 247–261 (PMID: 23409610).

Different regimen

7. Lewek M, Stevens J and Snyder-Mackler L. The use of electrical stimulation to increase quadriceps femoris muscle force in an elderly patient following a total knee arthroplasty. *Phys Ther* 2001; 81(9): 1565–1571 (PMID: 11688592).

Different regimen

8. Mayer M, Grulichová J and Bazala J. Some manoeuvres for releasing the hypertonus of spastic and shortened muscles. *Acta Univ Palacki Olomuc Fac Med* 1999; 142: 85–87 (PMID: 10743732).

Different regimen

9. McRoberts WP and Roche M. Novel approach for peripheral subcutaneous field stimulation for the treatment of severe, chronic knee joint pain after total knee arthroplasty. *Neuromodulation* 2010; 13(2): 131–136. Epub ahead of print 20 November 2009. DOI:10.1111/j.1525-1403.2009.00255.x (PMID: 21992788).

Different regimen

10. Narouze SN, Zakari A and Vydyanathan A. Ultrasound-guided placement of a permanent percutaneous femoral nerve stimulator leads for the treatment of intractable femoral neuropathy. *Pain Physician* 2009; 12(4): E305–E308 (PMID: 19668289).

Different regimen

11. Taverner MG, Ward TL and Loughnan TE. Transcutaneous pulsed radiofrequency treatment in patients with painful knee awaiting total knee joint replacement. *Clin J Pain* 2010; 26(5): 429–432. DOI:10.1097/AJP.0b013e3181d92a87 (PMID: 20473051).

Different regimen

12. Walker RH, Morris BA, Angulo DL, et al. Postoperative use of continuous passive motion, transcutaneous electrical nerve stimulation, and continuous cooling pad following total knee arthroplasty. *J Arthroplasty* 1991; 6(2): 151–156 (PMID: 1875206).

13. Wanich T, Gelber J, Rodeo S, et al. Percutaneous neuromodulation pain therapy following knee replacement. *J Knee Surg* 2011; 24(3): 197–202 (PMID: 21980881).